Announces that it has received a Notice of Allowance for the Company's U.S. patent application entitled "Cannabidiol Compositions for Use in Treating Heart Conditions" from the United States Patent and Trademark Office. Once issued, the new patent will establish broad intellectual property (I.P.) protection for the use of CardiolRx™ and CRD-38 in the treatment or prevention of an extensive range of cardiac conditions, including heart failure, myocarditis, acute pericarditis, inflammatory cardiomyopathy, cardiac toxicity from anti-cancer therapies, and atherosclerosis, to October 2040. Cardiol Therapeutics Inc. shares T.CRDL are trading up $0.01 at $1.47.
Stocks in play: Cardiol Therapeutics Inc.
Baystreet - Contributor Content 
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
/Adobe%20Inc%20logo%20on%20computer-by%20DANIEL%20CONSTANTE%20via%20Shutterstock.jpg)
/A%20Palantir%20office%20building%20in%20Tokyo_%20Image%20by%20Hiroshi-Mori-Stock%20via%20Shutterstock_.jpg)
/Micron%20Technology%20Inc_billboard-by%20Poetra_RH%20via%20Shutterstock.jpg)
